From Guidelines to Real Life—Multidisciplinary Insights for Optimizing Intravesical Bacillus Calmette–Guérin (BCG) Therapy in NMIBC

Intravesical Bacillus Calmette-Guérin (BCG) therapy remains the mainstay of treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), yet suboptimal adherence and underutilization of maintenance therapy limit real-world outcomes. This commentary summarizes multidisciplinary insights from an expert symposium at the European Association of Urology 2026 meeting, focusing on practical strategies to optimize treatment delivery. Key themes included the critical role of patient education, proactive toxicity management, and consistent multidisciplinary communication in improving adherence to prolonged BCG regimens. Treatment-related adverse events were identified as a major driver for discontinuation, although evidence suggests that true biologic intolerance to BCG is uncommon when best practices are implemented. Substantial clinical evidence indicates that maintenance BCG, rather than induction therapy alone, is necessary to reduce recurrence and progression risk.

Authors

Institutions

Publication Details

Journal
Oncology and Therapy
Published
2026-11-13
DOI
https://doi.org/10.1007/s40487-026-00470-7
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From Guidelines to Real Life—Multidisciplinary Insights for Optimizing Intravesical Bacillus Calmette–Guérin (BCG) Therapy in NMIBC

Paramananthan Mariappan, Ashish M. Kamat, Kathryn Chatterton, Niyati Lobo
4 links
Oncology and Therapy
Bladder and Urothelial Cancer Treatments
article

From Guidelines to Real Life—Multidisciplinary Insights for Optimizing Intravesical Bacillus Calmette–Guérin (BCG) Therapy in NMIBC

Paramananthan Mariappan, Ashish M. Kamat, Kathryn Chatterton, Niyati Lobo
article en

Abstract

Intravesical Bacillus Calmette-Guérin (BCG) therapy remains the mainstay of treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), yet suboptimal adherence and underutilization of maintenance therapy limit real-world outcomes. This commentary summarizes multidisciplinary insights from an expert symposium at the European Association of Urology 2026 meeting, focusing on practical strategies to optimize treatment delivery. Key themes included the critical role of patient education, proactive toxicity management, and consistent multidisciplinary communication in improving adherence to prolonged BCG regimens. Treatment-related adverse events were identified as a major driver for discontinuation, although evidence suggests that true biologic intolerance to BCG is uncommon when best practices are implemented. Substantial clinical evidence indicates that maintenance BCG, rather than induction therapy alone, is necessary to reduce recurrence and progression risk.

Oncology and Therapy
The University of Texas MD Anderson Cancer Center (US), Guy's and St Thomas' NHS Foundation Trust (GB), Western General Hospital (GB), Cambridge University Hospitals NHS Foundation Trust (GB), Edinburgh Cancer Research (GB), Thomas Foundation (AU), University of Edinburgh (GB)
Medac
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon